Trial Outcomes & Findings for Open-label Study of the Efficacy of Intranasal Oxytocin in Schizophrenia (NCT NCT02144155)

NCT ID: NCT02144155

Last Updated: 2019-12-09

Results Overview

The three subscales of the PANSS include the Positive scale (7 items), the Negative scale (7 items), and the General Psychopathology scale (16 items). The total PANSS score is the sum of all 30 items of which each item is scored on a 1-7 rating system (7 indicating the worst symptoms). The items on the PANSS focus on symptoms that are common in patients with psychotic disorders and include hallucinations, delusions and disorganization as well as mood disturbances.

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

14 participants

Primary outcome timeframe

baseline and 28 weeks

Results posted on

2019-12-09

Participant Flow

Participant milestones

Participant milestones
Measure
All Participants
This study was halted due to an indefinite break in funding. The Principal Investigator has left the institution and there is no way to determine the arms/groups of this study.
Overall Study
STARTED
14
Overall Study
COMPLETED
14
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

The PI has left the institution and this study was terminated due to loss of funding. The age of the participants enrolled cannot be located.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
All Participants
n=14 Participants
This study was halted due to an indefinite break in funding. The Principal Investigator has left the institution and there is no way to determine the arms/groups of this study.
Sex: Female, Male
Female
6 Participants
n=14 Participants
Sex: Female, Male
Male
8 Participants
n=14 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=14 Participants
Race (NIH/OMB)
Asian
0 Participants
n=14 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=14 Participants
Race (NIH/OMB)
Black or African American
7 Participants
n=14 Participants
Race (NIH/OMB)
White
5 Participants
n=14 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=14 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
n=14 Participants

PRIMARY outcome

Timeframe: baseline and 28 weeks

Population: The PI has left the institution and this study was terminated due to loss of funding. The data was not analyzed.

The three subscales of the PANSS include the Positive scale (7 items), the Negative scale (7 items), and the General Psychopathology scale (16 items). The total PANSS score is the sum of all 30 items of which each item is scored on a 1-7 rating system (7 indicating the worst symptoms). The items on the PANSS focus on symptoms that are common in patients with psychotic disorders and include hallucinations, delusions and disorganization as well as mood disturbances.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 28 weeks

Population: The PI has left the institution and this study was terminated due to loss of funding. The data was not analyzed.

The GAF considers psychological, social, and occupational functioning on a hypothetical continuum of mental health illness. Scores on the GAF range from 1 (extremely severe) to 100 (superior functioning).

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 28 Weeks

Population: The PI has left the institution and this study was terminated due to loss of funding. The data was not analyzed.

The CGI-S is used to evaluate changes in overall severity of illness. Scores range from 1 (not at all) to 7 (among the most extremely ill).

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 28 Weeks

Population: The PI has left the institution and this study was terminated due to loss of funding. The data was not analyzed.

The CGI-I is a global assessment to evaluate the subject's improvement or worsening from baseline. Scores on the CGI-I scale range from 1 (very much improved) to 7 (very much worse).

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 28 weeks

Population: The PI has left the institution and this study was terminated due to loss of funding. The data was not analyzed.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 28 Weeks

Population: The PI has left the institution and this study was terminated due to loss of funding. The data was not analyzed.

Outcome measures

Outcome data not reported

Adverse Events

All Participants

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

David Feifel

UCSD

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place